SLB announced its ChampionX nano-enabled chemical portfolio on November 4, 2026. One application is scale control: treating wells to limit mineral deposits that can restrict flow. SLB says its Extended Release technology lasted more than twice as long as conventional scale-squeeze treatments in offshore deployments. That is a result the company reports for those deployments. It does not establish how long treatment will last in another well.
Agree on what counts as the end of treatment
SLB describes nano-enabled scale chemistry as a way to help retain inhibitor and release it gradually as fluids are produced. Before comparing two treatments, ask which observation ended each measured period: a drop below a defined inhibitor concentration, a verified return of scale, or the date the team decided to treat again. Those dates can differ. Write down the endpoint and sampling schedule before comparing the numbers.
Separate confirmed duration from the next intervention
Imagine a conventional treatment stayed above a chosen threshold for 90 days. A trial stayed above the same threshold at its last sample on day 150, and the well was treated again on day 180 without another sample. The trial has 150 days of confirmed evidence under that definition. Day 180 tells you when the intervention happened, but it does not prove that the threshold was met until then.
Ask what else changed
Compare operating conditions, treatment dose, sampling frequency and interruptions. If fluid production or the scale risk changed, a longer interval may reflect more than the chemistry. Keep treatment duration, production changes and intervention costs as separate results. For a purchasing or pilot decision, ask the supplier for the comparable baseline and the evidence behind each reported endpoint.
Check the comparison
Sources
SLB’s November 4 launch announcement